As Delhi's hospitals strain under a convergence of seasonal illnesses, an H1N1 surge has exposed a quiet but consequential gap in India's public health infrastructure: the preferred flu vaccine is simply not there. India's medical research council has responded with pragmatic guidance — use the Southern Hemisphere formulation now, and switch when the better-matched Northern version arrives. The episode is a reminder that in a globally entangled vaccine supply chain, the most vulnerable populations often find themselves last in line, navigating a choice between imperfect protection and none at
ICMR recommends Southern Hemisphere flu vaccine as Northern variant faces shortage
Vulnerable populations including elderly, young children, pregnant women and immunocompromised individuals face increased risk of severe influenza complications including pneumonia and hospitalization.
Don't wait for the preferred vaccine if it means staying unvaccinated.
Mark
So ICMR is saying the Northern Hemisphere vaccine is better for India right now, but it's not available. Why does geography matter so much with flu shots?
Mimi
The flu virus mutates constantly. Every year, the WHO recommends different strain combinations for the Northern and Southern Hemispheres based on which viruses are expected to spread during each region's coming flu season. This year, the viruses circulating in India happen to match the Northern Hemisphere recommendation more closely.
Luke
But wait—India is geographically in the Northern Hemisphere. So shouldn't it always use that vaccine?
Mimi
That's what you'd think, but no. Dr. Tarun Kumar from Medanta Moolchand pointed out that India's flu patterns don't follow the classic European or North American winter cycle. Some years the Southern Hemisphere vaccine is actually the better match.
Mark
Okay, so this year it's the Northern one. But it's gone. What do doctors say about using the Southern Hemisphere vaccine instead?
Mimi
They say it works well in India too. The H1N1 virus is covered by both. The difference is in H3N2 and Influenza B—the Northern vaccine has strains that are a closer match to what's spreading here. But the Southern vaccine still protects against all three viruses.
Luke
So it's not a bad option, just a less optimal one. But for high-risk people—elderly, pregnant women, immunocompromised—waiting for the preferred vaccine could be dangerous.
Mimi
Exactly. Influenza can cause pneumonia and hospitalization in vulnerable groups. Doctors are saying don't wait; take what's available.
Mark
Why is the Northern Hemisphere vaccine in such short supply?
Mimi
Manufacturers plan production based on demand forecasts. This year demand jumped two to three times higher because of the H1N1 surge. But there are also global supply chain issues—limited imports, production delays, and some countries getting priority.
Luke
So it's not just that more people want it. It's also that the global system for distributing vaccines isn't set up to handle sudden spikes in one region.
Mimi
Right. And India doesn't have a public vaccination program for flu, so people buy privately. That means the market is smaller and less predictable than it would be if the government was ordering in bulk.
Mark
When will the Northern Hemisphere vaccine actually be available?
Mimi
Supplies of the Southern Hemisphere vaccine were expected by the end of the week. But the Northern vaccine—that's still unclear. The shortage reflects deeper production and redistribution delays.
O Pulso
- Delhi's hospitals are simultaneously managing H1N1, dengue, typhoid, and other seasonal illnesses, pushing wards toward a triage footing.
- The Northern Hemisphere flu vaccine — better matched to strains currently circulating in India — has run dry at the hospital level, with no government supply available.
- Demand for flu shots surged two to three times above forecasts this season, catching manufacturers and distributors unprepared and leaving shelves empty.
- ICMR has issued a direct workaround: the Southern Hemisphere vaccine protects against H1N1 and should be used immediately rather than waiting for the preferred formulation.
- Southern Hemisphere supplies were expected by week's end, but production delays and unequal global distribution mean the underlying shortage will not resolve swiftly.
- High-risk groups — the elderly, pregnant women, young children, and the immunocompromised — face the sharpest edge of this shortage, forced to choose between a less-optimal vaccine and remaining unprotected.
As Delhi's hospitals strain under a convergence of seasonal illnesses, an H1N1 surge has exposed a quiet but consequential gap in India's public health infrastructure: the preferred flu vaccine is simply not there. India's medical research council has responded with pragmatic guidance — use the Southern Hemisphere formulation now, and switch when the better-matched Northern version arrives. The episode is a reminder that in a globally entangled vaccine supply chain, the most vulnerable populations often find themselves last in line, navigating a choice between imperfect protection and none at all.
Delhi is in the grip of an H1N1 surge, and its hospitals are absorbing it alongside dengue, typhoid, and the usual cluster of seasonal illnesses. This week, the Indian Council of Medical Research issued a statement that doubles as a practical concession: the flu vaccine most suited to this season's circulating strains is unavailable, so the alternative will have to do.
ICMR has been running influenza surveillance across 73 sites since July 2025, with samples sequenced at the National Influenza Centre in Pune — a WHO Collaborating Centre embedded in the global flu-watching network. Of 49 sequenced samples, H3N2 dominated nationally, but H1N1 is what has driven the recent Delhi spike. All three strains — H1N1, H3N2, and Influenza B Victoria — are currently circulating.
The Northern Hemisphere vaccine is preferred because its H3N2 and Influenza B components more closely match what is actually spreading in India this season. The Southern Hemisphere version covers H1N1 effectively but is a less precise fit for the other two strains. In a normal year, both are available. This year, the Northern formulation has run out. Dr. Ramesh Chand Meena of Dr Ram Manohar Lohia Hospital confirmed the gap is real: there is no government supply in any hospital.
The shortage traces back to a collision of forces — demand that surged two to three times above forecasts, manufacturing timelines that could not flex quickly enough, and a global redistribution system in which some countries receive priority over others. GSK is among the major suppliers affected. Southern Hemisphere stocks were expected to reach the market by week's end, but the structural problem will not resolve on that timeline.
ICMR's guidance is clear: high-risk groups — older adults, young children, pregnant women, people with chronic illness or compromised immunity — should not wait. The Southern Hemisphere vaccine now is better than no vaccine while the virus is circulating. India has no public flu immunization program; shots are obtained privately at roughly 2,000 to 2,500 rupees, a price that has historically kept uptake low. This year, more people sought protection — and found the supply had not kept pace with the moment.
Delhi is in the grip of an H1N1 surge, and hospitals are buckling under the weight of it. The flu cases are arriving alongside dengue, typhoid, and other seasonal illnesses that always cluster in the same months, turning wards into triage zones. This week, India's medical research council issued a statement that amounts to a practical surrender: the flu vaccine everyone prefers is not available, so use the other one instead.
The Indian Council of Medical Research, or ICMR, has been tracking influenza across 73 surveillance sites nationwide since July 2025, collecting samples and sending them to the National Influenza Centre at its National Institute of Virology in Pune. That lab functions as a WHO Collaborating Centre, part of the global system for watching flu strains as they move. Of the 73 samples received, 49 were sequenced in detail. The results showed three were H1N1, 52 were H3N2, and 18 were Influenza B Victoria. H3N2 dominates the national picture, but H1N1 is what has driven the recent spike in Delhi specifically. All three viruses are circulating in India right now.
The Northern Hemisphere vaccine—the one ICMR says would be ideal—contains versions of H3N2 and Influenza B that match more closely with what is actually spreading in India this season. The Southern Hemisphere vaccine protects against the same H1N1 virus, but its versions of the other two strains are less well matched to current Indian strains. In a normal year, both vaccines are available and used. This year, the Northern version is in short supply. ICMR's recommendation, issued Wednesday, was direct: use the Southern Hemisphere vaccine now, and switch to the Northern version as soon as it arrives. Dr. Ramesh Chand Meena, an associate professor of medicine at Dr Ram Manohar Lohia Hospital in New Delhi, confirmed the shortage is real at the hospital level. "There is no government supply of this vaccine in any hospital," he said.
Why the shortage? The answer is tangled. Manufacturers plan production based on demand forecasts, and this year demand surged two to three times higher than in previous years as people sought protection during the H1N1 wave. GSK is among the largest suppliers, but limited imports and delays in shipments have left distributors empty. Dr. Raj Shankar Ghosh, a senior physician and public health expert at the Public Health Foundation of India, points to something broader: a combination of manufacturing timelines, global redistribution of vaccines, and some countries receiving priority over others. Supplies of the Southern Hemisphere vaccine were expected to reach the market by the end of the week, but the underlying problem—production delays and unequal global access—will not resolve quickly.
For most healthy people, influenza is self-limiting. For others, it is not. Older adults, young children, pregnant women, and people with chronic illnesses or weakened immune systems face the risk of pneumonia, hospitalization, and worsening of existing conditions. Doctors say these high-risk groups should not wait for the preferred vaccine if it is unavailable. Taking the Southern Hemisphere shot now is better than remaining unvaccinated. India does not provide annual flu vaccination through its public immunization program; people obtain it privately, typically at a cost of 2,000 to 2,500 rupees. That price barrier has traditionally kept uptake low, but this year more people have sought protection. The shortage, then, arrives at a moment when demand is actually climbing—a collision between rising need and constrained supply that leaves vulnerable populations in a difficult position: accept a less-optimal vaccine or wait and hope the preferred one arrives before the virus does.
Citações Notáveis
There is no government supply of this vaccine in any hospital.— Dr. Ramesh Chand Meena, associate professor of medicine at Dr Ram Manohar Lohia Hospital, New Delhi
India is geographically in the Northern Hemisphere, but influenza circulation in India does not always follow the classic European/North American winter pattern.— Dr. Tarun Kumar, Director and Head, Medanta Moolchand Heart Centre
Quer a matéria completa?
Leia o original em ThePrint ↗
Health & Medicine